Go Therapeutics Signs $195 Million Licensing Deal with Roche

GO Therapeutics of Cambridge, Mass. signed a $195 million licensing deal with Roche to develop antibodies for cancer. One year ago, Shenzhen Salubris made a $5 million investment in GO, acquiring China rights to GO's future products as part of the deal. GO uses advances in glycobiology to develop cancer drugs that it hopes will prove to be more potent and less toxic. The pre-clinical company develops cancer-specific antibodies that can be used as antibody-drug conjugates, bispecific T-cell engagers and immune-based cell therapies. More details....

Stock Symbol: (SWX: ROG) (SHZ: 2294)

Share this with colleagues:

Original Article: Go Therapeutics Signs $195 Million Licensing Deal with Roche

More From BioPortfolio on "Go Therapeutics Signs $195 Million Licensing Deal with Roche"